Individual analysis of the three different tetraspanin-positive subpopulations revealed that among the subgroup of CD81+ EVs, a large increase in the percentage of FASN+ EVs occurred in glioblastoma patients compared to healthy individuals (mean 64.3% GBM vs 33.0% HD, P = 0.0006) and also in anaplastic astrocytoma patients (mean 69.06% AA vs 33.0% HD, P = 0.006) (Figure 4D). This evidence concerns the gene CD81 and glioblastoma.